Q1 2023 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Conclusions
Financial performance
Immunology
TNO155-SHP2 inhibitor
Indication
Phase
NCT03114319 (CTNO155X2101)
Solid tumors (single agent)
Phase 1
Patients
255
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Number of participants with adverse events
Number of participants with dose limiting toxicities
Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)
Adult patients with advanced solid tumors in selected indications
Readout
Milestone(s)
Publication
2024
TBD
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
References
Abbreviations
Other
81 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation